AbbVie Buying Landos Biopharma In $137.5 Million Deal

By Amit Chowdhry • Mar 25, 2024

AbbVie and Landos Biopharma announced a deal under which AbbVie will acquire Landos, a clinical-stage biopharmaceutical company focused on developing novel, oral therapeutics for patients with autoimmune diseases. Landos’ lead investigational asset is NX-13, which is an oral NLRX1 agonist (a member of the NOD-like receptor family) with a bimodal mechanism of action (MOA). It is anti-inflammatory and facilitates epithelial repair.

NLRX1 regulates immunometabolism and inflammation and the activation impacts multiple mechanisms of inflammatory bowel disease (IBD) pathogenesis. The randomized controlled Phase 2 NEXUS clinical trial evaluating NX-13 in UC is now enrolling patients in the United States and Europe (NCT05785715).

Under the terms of the agreement, AbbVie will buy Landos at $20.42 per share in cash upon closing (or about $137.5 million in the aggregate), plus one non-tradable contingent value right per share with a value of up to $11.14 per share, or about an additional $75 million in the aggregate, subject to the achievement of a clinical development milestone. The proposed deal is expected to close in the second calendar quarter of 2024, subject to customary closing conditions, including approval by Landos’ stockholders.


“With this acquisition, we aim to advance the clinical development of NX-13, a differentiated, first-in-class, oral asset with the potential to make a difference in the lives of people living with ulcerative colitis and Crohn’s disease.”

– Roopal Thakkar, M.D., senior vice president, chief medical officer, global therapeutics, AbbVie

“This announcement is a testament to Landos’ talented team and their commitment to our mission of creating oral treatments that can address a therapeutic gap. NX-13 and its bimodal MOA have the potential to provide a novel approach to the treatment of ulcerative colitis and Crohn’s disease. With AbbVie’s therapeutic area leadership and expertise in global development, they are the right company to further advance NX-13.”

– Gregory Oakes, president and chief executive officer, Landos